Marty Chilberg
Long only, special situations, research analyst, healthcare

Market Outlook: Non-Invasive Prenatal Screening Poised For Significant Growth

Summary

The NIPS (see abbreviations) market has exhibited significant growth since the late 2011 introduction of MaterniT21. Market acceptance has been most significant in the United States, which generated estimated revenues of $200 million in 2013. Though fewer disclosures have been seen relating to revenues in other major markets, several are discussed in this report including: Brazil and Mexico in the Americas; China, India, Japan in Asia; and the EU5. Demographic information relevant to NIPS is also summarized by region.

US market 2013 revenues (estimated)

  1. MaterniT21 Plus (Sequenom) $90 million
  2. Harmony (Ariosa Diagnostics) $40 million
  3. Panorama (Natera) $25 to $35 million
  4. Verifi (Illumina) $15 to $25 million

Products or rebrands available outside the US

    NIFTY (BGI) - Estimated...
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details